Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors
C Shao, G Li, L Huang, S Pruitt… - JAMA Network …, 2020 - jamanetwork.com
Importance Tumor mutational burden (TMB) is a potential biomarker associated with
response to immune checkpoint inhibitor therapies. The prognostic value associated with …
response to immune checkpoint inhibitor therapies. The prognostic value associated with …
[HTML][HTML] Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck …
RI Haddad, TY Seiwert, LQM Chow… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background To characterize genomic determinants of response to pembrolizumab in
recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the …
recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the …
[HTML][HTML] Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer
K Emancipator, L Huang, D Aurora-Garg, T Bal… - Modern Pathology, 2021 - Elsevier
Tumor proportion score (TPS) and combined positive score ([CPS] includes immune cells), 2
methods for scoring programmed death ligand 1 (PD-L1) expression, have been used in …
methods for scoring programmed death ligand 1 (PD-L1) expression, have been used in …
[HTML][HTML] Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
M Ilie, S Khambata-Ford, C Copie-Bergman, L Huang… - PLoS …, 2017 - journals.plos.org
Background For non–small cell lung cancer (NSCLC), treatment with pembrolizumab is
limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) …
limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) …
Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell …
M Ilie, J Juco, L Huang, V Hofman… - Cancer …, 2018 - Wiley Online Library
BACKGROUND Pembrolizumab monotherapy is a standard‐of‐care treatment for the first‐
and second‐line treatment of advanced non–small cell lung cancer with programmed death …
and second‐line treatment of advanced non–small cell lung cancer with programmed death …
Transcriptomic determinants of response to pembrolizumab monotherapy across solid tumor types
R Cristescu, M Nebozhyn, C Zhang, A Albright… - Clinical Cancer …, 2022 - AACR
Purpose: To explore relationships between biological gene expression signatures and
pembrolizumab response. Experimental Design: RNA-sequencing data on baseline tumor …
pembrolizumab response. Experimental Design: RNA-sequencing data on baseline tumor …
Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple …
EP Winer, O Lipatov, SA Im, A Goncalves… - 2020 - ascopubs.org
1013 Background: In the randomized, open-label, phase 3 KEYNOTE-119 study
(NCT02555657), OS was not significantly different with pembro monotherapy versus chemo …
(NCT02555657), OS was not significantly different with pembro monotherapy versus chemo …
[PDF][PDF] Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types
A Chhibber, L Huang, H Zhang, J Xu, R Cristescu… - Immunity, 2022 - cell.com
We evaluated the impact of class I and class II human leukocyte antigen (HLA) genotypes,
heterozygosity, and diversity on the efficacy of pembrolizumab. Seventeen pembrolizumab …
heterozygosity, and diversity on the efficacy of pembrolizumab. Seventeen pembrolizumab …
Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
6009 Background: Somatic mutational load (ML) is associated with response to anti CTLA-4
and PD-1/-L1 immunotherapies in select tumors, due to formation of neoepitopes not subject …
and PD-1/-L1 immunotherapies in select tumors, due to formation of neoepitopes not subject …
Association between biomarkers and clinical outcomes of pembrolizumab monotherapy in patients with metastatic triple-negative breast cancer: KEYNOTE-086 …
S Loi, R Salgado, P Schmid, J Cortes… - JCO precision …, 2023 - ascopubs.org
PURPOSE In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials. gov identifier:
NCT02447003), first-line and second-line or later pembrolizumab monotherapy …
NCT02447003), first-line and second-line or later pembrolizumab monotherapy …